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Insomnia is rife. Acutely, almost every individual has experienced a poor night’s sleep, 
and many short-term remedies for insomnia are tried, including over-the-counter sleep 
aids and alcohol. Chronic insomnia is the most common sleep disorder, affecting 
nearly 40 million Americans and accounting for nearly one-third of adults. The annual 
cost associated with this disorder in the US is estimated at over $15 billion1 and over 
$100 billion for indirect costs, such as costs of self-medication, health care-related 
costs due to exacerbations of comorbid conditions, and costs of reduced productivity.2 
Degradations of sleep quantity and sleep quality in insomnia have been associated with 
deleterious long-term effects, including cardiovascular, endocrine, psychological, and 
immune system complications. Despite these facts, chronic insomnia is not always 
perceived as a treatable and important medical condition. Symptoms are not always 
proffered by patients, and diagnoses can be ignored by physicians, partly because 
insomnia is so common that it is considered somewhat normal, particularly in elderly 
individuals. These days, recognized treatments for insomnia include pharmacologi-
cal therapies and the more recently accepted behavioral therapies, including stimulus 
control, relaxation, and cognitive and behavioral therapy. Research to evaluate and 
formulate treatments for insomnia is often beset by the problem that insomnia is usu-
ally of multifactorial etiology among individuals. Thus, complex and important ques-
tions remain, eg, which types of insomnia can be cured, which therapy is best in each 
situation and in each patient, and why do so many untreated or suboptimally treated 
individuals with insomnia exist? There is also a clear need to examine the long-term 
effects of treatment on diverse cultures, ages, and races and in those with comorbid 
disorders, using randomized clinical trials of sufficient duration.
In the first full year of publication, the Nature and Science of Sleep (NSS) has 
published a set of articles that begins to examine the advantages and limitations of a 
number of relatively novel pharmacological and behavioral therapies for insomnia. 
These papers ought to help clinicians appraise new therapies, better manage insomnia, 
and identify important gaps in our knowledge and promising future approaches.
A number of papers in NSS review new pharmacological strategies for insomnia 
therapy, including the use of nonbenzodiazepine gamma-aminobutyric acid   receptor 
agonists such as zolpidem, zaleplon, and eszopiclone (Z-drugs), which potentially 
have reduced adverse effects with improved safety and tolerance compared with older 
benzodiazepines;9 the melatonin receptor agonist ramelteon;12 serotonin receptor 
antagonists;6 and therapies with novel routes of administration, such as oral spray and Nature and Science of Sleep 2011:3 submit your manuscript | www.dovepress.com
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sublingual tablets.7,11 For instance, administration of zolpidem 
via a rapid-absorption oral spray or a sublingual tablet can 
have advantages due to faster onset of action, lower dose 
requirement, better patient compliance and convenience, 
and increased bioavailability. Because the Z-drugs are rapid 
action, they could be used for short-term insomnia, with the 
precaution that fast-acting drugs could have potentially faster 
side effects and pose an increased risk for accidental overdose 
or abuse of the drugs. Moreover, further studies are needed 
to establish safety, particularly in terms of the carryover of 
excessive sleepiness into the daytime.11
Sleep patterns change with increasing age.   Typically, sleep 
is lighter, more fragmented, and shorter,9 and the presence of 
comorbid conditions that interfere with sleep, such as chronic 
pain, depression, chronic   obstructive   pulmonary disease 
(COPD), and congestive heart   failure, also lead to a higher 
prevalence of insomnia in the elderly. An article in NSS high-
lights the fact that insomnia is associated with an increased 
risk of hypertension and cardiovascular disease.13 This inter-
relationship between insomnia and   disease can precipitate 
a vicious circle whereby insomnia can exacerbate disease, 
which can further exacerbate insomnia. Moreover, interpreta-
tion of clinical trials in the elderly becomes challenging due 
to confounding effects of medications for these comorbid 
conditions, and decreased clearance of sleep medications. 
To solve this challenging question, a paper in NSS specifically 
reviews pharmacotherapy for insomnia in the elderly4 and 
concludes that eszopiclone is well suited, improving quality 
of life without the development of drug tolerance and with-
out rebound insomnia after discontinuation. Similarly, some 
promise was suggested for the use of 5-hydroxytryptamine 
2A (5-HT2A) antagonists in treating sleep maintenance 
insomnia.6 Ramelteon was helpful in sleep onset insomnia 
and circadian rhythm disorder, with no rebound insomnia and 
reportedly no abuse potential. Ramelteon also did not exac-
erbate respiratory disorders such as sleep apnea and COPD, 
which is a concern for other sedative medications that can 
depress   ventilation or arousal responses.12 Understanding the 
molecular and receptor mechanisms involved in promoting 
sleep in varied disorders could provide future approaches in 
new drug development. In the long term, more randomized 
controlled trials are needed to assess both short-term and 
long-term effects of these medications and their efficacy in 
comorbid diseases that affect sleep quality or quantity.
In search of a better therapeutic approach for insomnia 
there is an emerging debate about using pharmacotherapy 
and behavioral therapy to manage insomnia. One of the first 
studies to formally address this debate using a randomized 
placebo-controlled trial was published in 1999 and 
demonstrated that a combined pharmacological and cognitive 
behavioral therapy for insomnia (CBT-I) was very effective, 
particularly in terms of duration of effect. Although this was 
the largest clinical trial in the field at that time, the sample 
size was relatively small (n = 78), included only elderly 
people, and the pharmacotherapy included one medication, 
temazepam. Thus, this result cannot be generalized to a wider 
population or other drugs.3
In this regard, recent papers in NSS have begun to 
examine CBT-I in varied populations. For instance, a pilot 
randomized controlled crossover study in breast cancer 
survivor patients suggested that individualized CBT-I therapy 
sessions continued to improve sleep quality.10 Furthermore, 
two studies examined the efficacy of CBT-I in pediatric 
populations and showed promising results.14,15 Novel 
multimodal controlled therapies in children aged 5–10 years 
combined with training sessions with their parents revealed 
better efficacy and improved compliance.14 This novel age-
appropriate treatment program was also very effective in 
improving sleep efficiency in children aged 11–17 years, 
possibly reflecting better acceptance in this age group.15
CBT-I contains components such as psychotherapy, 
sleep restriction, paradoxical intention, stimulus control, 
sleep hygiene, relaxation training, and biofeedback. These 
techniques can be effective in many patients, but a common 
problem is accessibility to CBT-I.5 Also, the relative efficacy 
of individual psychological therapeutic techniques within 
the components of CBT-I still needs to be evaluated in 
appropriately controlled studies.
Additional individual novel therapies for insomnia are 
reviewed in NSS, such as Internet-based interventions, bright 
light treatments, intensive sleep retraining, mindfulness 
meditation, and acupuncture, and these are assessed for 
comparative effectiveness with the goal of improved 
outcomes, reduced costs, and/or improved compliance. 
Many of these approaches have encouraging findings but 
still require further research, including randomized placebo-
controlled trials, to establish their effectiveness.8
Finally, due to the importance of adequate insomnia 
management, in its first full year, NSS has published numerous 
original articles that highlight the relative efficacy of specific 
therapies over others and in specific patient populations. 
Specifically, NSS has published 12 articles on novel 
pharmacological and cognitive behavioral therapeutic methods 
for relieving insomnia in varied populations, including chil-
dren, adolescents, adults, and the elderly. Additionally, NSS 
has published focused reviews on insomnia with comorbid Nature and Science of Sleep
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conditions, as well as other novel therapeutic options. These 
informative reviews point out that there is a need for future 
long-term clinical trials. As mentioned previously, due to the 
complexity and multifactorial etiology of insomnia, many 
questions remain unanswered. We encourage you to continue 
your research to provide tailored approaches to managing 
insomnia in specific populations or individuals, to publish 
your research in NSS, and to help put insomnia to sleep.
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